BBIO: BridgeBio Pharma Inc. Stocks News on November 21, 2024

BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market

BBIO

Benzinga

2 days ago

BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market

BBIO

Simply Wall St.

2 days ago

The Consensus EPS Estimates For BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Fell Dramatically

Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

BBIO

GlobeNewswire

3 days ago

Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months

BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia

BBIO

GlobeNewswire

4 days ago

BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia

BridgeBio Pharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

BBIO

Simply Wall St.

8 days ago

BridgeBio Pharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

BBIO

Morningstar Research

9 days ago

Analyst Report: BridgeBio Pharma, Inc.

BBIO

Zacks

9 days ago

BridgeBio Pharma (BBIO) Reports Q3 Loss, Lags Revenue Estimates

BBIO

MT Newswires

9 days ago

BridgeBio Pharma's Q3 Loss Narrows, Revenue Declines

BBIO

Associated Press Finance

9 days ago

BridgeBio Pharma: Q3 Earnings Snapshot

BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update

BBIO

GlobeNewswire

9 days ago

BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update

BridgeBio Announces Publication of Case Study Exploring Portfolio Theory’s Impact on Biomedical Innovation in The Journal of Portfolio Management

BBIO

GlobeNewswire

16 days ago

BridgeBio Announces Publication of Case Study Exploring Portfolio Theory’s Impact on Biomedical Innovation in The Journal of Portfolio Management

BBIO

Zacks

21 days ago

BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024

BBIO

GlobeNewswire

a month ago

BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024

BBIO

Simply Wall St.

a month ago

Investors in BridgeBio Pharma (NASDAQ:BBIO) have unfortunately lost 49% over the last three years

BBIO

MT Newswires

a month ago

Scotiabank Initiates BridgeBio Pharma at Sector Outperform With $44 Price Target

3 Top Stocks That Could Still Rocket Higher in 2024

BBIO

Motley Fool

2 months ago

3 Top Stocks That Could Still Rocket Higher in 2024

BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions

BBIO

GlobeNewswire

2 months ago

BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions

BBIO

MT Newswires

2 months ago

Oppenheimer Initiates BridgeBio Pharma at Perform

5 FDA decisions to watch in the fourth quarter

BBIO

BioPharma Dive

2 months ago

5 FDA decisions to watch in the fourth quarter

BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease

BBIO

Benzinga

2 months ago

BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease

BBIO

Morningstar Research

2 months ago

Analyst Report: BridgeBio Pharma, Inc.

BBIO

MT Newswires

2 months ago

BridgeBio Pharma Completes Phase 3 BBP-418 Trial Enrollment

BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

BBIO

GlobeNewswire

2 months ago

BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events

BBIO

GlobeNewswire

2 months ago

BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events

BBIO

MT Newswires

2 months ago

Sector Update: Health Care Stocks Steady Premarket Tuesday

BBIO

MT Newswires

2 months ago

BridgeBio Pharma Says Infigratinib Receives US FDA Breakthrough Therapy Designation

BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA

BBIO

GlobeNewswire

2 months ago

BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA

The Brawl Taking Shape Over Pfizer’s Multibillion-Dollar Heart Monopoly

BBIO

The Wall Street Journal

2 months ago

The Brawl Taking Shape Over Pfizer’s Multibillion-Dollar Heart Monopoly

BridgeBio Pharma Seeks Partner To Develop Gene Therapy For Inherited Condition

BBIO

Benzinga

2 months ago

BridgeBio Pharma Seeks Partner To Develop Gene Therapy For Inherited Condition

BridgeBio trims gene therapy budget after seeing data on adrenal gland medicine

BBIO

BioPharma Dive

2 months ago

BridgeBio trims gene therapy budget after seeing data on adrenal gland medicine

BBIO

MT Newswires

2 months ago

BridgeBio Pharma Cancels Development of Congenital Adrenal Hyperplasia Treatment

BBIO

MT Newswires

2 months ago

BridgeBio Pharma Gets RMAT Designation for Gene Therapy Targeting Canavan Disease

BridgeBio Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program

BBIO

GlobeNewswire

2 months ago

BridgeBio Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program

BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)

BBIO

GlobeNewswire

2 months ago

BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BBIO

GlobeNewswire

2 months ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BBIO

MT Newswires

3 months ago

Piper Sandler Initiates BridgeBio Pharma at Overweight

BBIO

MT Newswires

3 months ago

Sector Update: Health Care Stocks Softer in Afternoon Trading

Why Is BridgeBio Pharma Stock Trading Higher On Friday?

BBIO

Benzinga

3 months ago

Why Is BridgeBio Pharma Stock Trading Higher On Friday?

BBIO

MT Newswires

3 months ago

BridgeBio Pharma Reports Positive Additional Data From Phase 3 Study of Acoramidis; Shares Rise

BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension

BBIO

GlobeNewswire

3 months ago

BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension

Alnylam Stock Falls on Positive but Disappointing Study Results for Heart Drug

BBIO

The Wall Street Journal

3 months ago

Alnylam Stock Falls on Positive but Disappointing Study Results for Heart Drug

BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024

BBIO

GlobeNewswire

3 months ago

BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024

BridgeBio Pharma to Participate in September Investor Events

BBIO

GlobeNewswire

3 months ago

BridgeBio Pharma to Participate in September Investor Events

BBIO

MT Newswires

3 months ago

BridgeBio Partners With CarDS Lab for Transthyretin Amyloid Cardiomyopathy Study

BridgeBio Partners with Leading Cardiovascular Data Science Lab (CarDS Lab) to Improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Diagnosis in Diverse Patient Populations with Multimodal Artificial Intelligence

BBIO

GlobeNewswire

3 months ago

BridgeBio Partners with Leading Cardiovascular Data Science Lab (CarDS Lab) to Improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Diagnosis in Diverse Patient Populations with Multimodal Artificial Intelligence

BBIO

MT Newswires

3 months ago

BridgeBio Pharma Launches GondolaBio Joint Venture

BridgeBio sends rare disease drugs to new company

BBIO

BioPharma Dive

3 months ago

BridgeBio sends rare disease drugs to new company

BridgeBio Launches MyAchonJourney, a New Resource for Families Navigating Achondroplasia

BBIO

GlobeNewswire

3 months ago

BridgeBio Launches MyAchonJourney, a New Resource for Families Navigating Achondroplasia

BBIO

GlobeNewswire

3 months ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

BBIO

Simply Wall St.

4 months ago

BridgeBio Pharma Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

BBIO

Zacks

4 months ago

BridgeBio Pharma (BBIO) Reports Q2 Loss, Misses Revenue Estimates

BBIO

Associated Press Finance

4 months ago

BridgeBio Pharma: Q2 Earnings Snapshot

BridgeBio Pharma Reports Second Quarter 2024 Financial Results and Business Update

BBIO

GlobeNewswire

4 months ago

BridgeBio Pharma Reports Second Quarter 2024 Financial Results and Business Update

BBIO

MT Newswires

4 months ago

BridgeBio Pharma Names New COO

BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer

BBIO

GlobeNewswire

4 months ago

BridgeBio Announces Appointment of Thomas Trimarchi, Ph.D., as President and Chief Operating Officer

BBIO

GlobeNewswire

5 months ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BBIO

Insider Monkey

5 months ago

BridgeBio Pharma, Inc. (BBIO): Is This Healthcare Stock a Strong Buy?

BBIO

MT Newswires

5 months ago

BridgeBio Surpasses Interim Analysis Enrollment Target in Limb-Girdle Muscular Dystrophy Trial

BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

BBIO

GlobeNewswire

5 months ago

BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

BBIO

GlobeNewswire

5 months ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference

BBIO

GlobeNewswire

5 months ago

BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference

BridgeBio Stock Gives Up Gains On Comparisons To BioMarin Drug

BBIO

Investor's Business Daily

6 months ago

BridgeBio Stock Gives Up Gains On Comparisons To BioMarin Drug

BBIO

MT Newswires

6 months ago

BridgeBio Pharma Phase 2 Trial of Infigratinib Shows 'Continued Well-Tolerated Safety Profile'; Starts Phase 3 Trial Enrollment

BridgeBio data show sustained benefit for achondroplasia drug

BBIO

BioPharma Dive

6 months ago

BridgeBio data show sustained benefit for achondroplasia drug

BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia

BBIO

GlobeNewswire

6 months ago

BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia

BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024

BBIO

GlobeNewswire

6 months ago

BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024

Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

BBIO

GlobeNewswire

6 months ago

Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

BBIO

MT Newswires

6 months ago

UBS Adjusts Price Target on BridgeBio Pharma to $47 From $51, Maintains Buy Rating

BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting

BBIO

GlobeNewswire

6 months ago

BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting

BBIO

Simply Wall St.

6 months ago

Party Time: Brokers Just Made Major Increases To Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Earnings Forecasts

BBIO

GlobeNewswire

6 months ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024

BBIO

GlobeNewswire

6 months ago

BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024

BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis of the Entire Study Population

BBIO

GlobeNewswire

6 months ago

BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensitivity Analysis of the Entire Study Population

BBIO

Simply Wall St.

7 months ago

What You Need To Know About The BridgeBio Pharma, Inc. (NASDAQ:BBIO) Analyst Downgrade Today

BridgeBio Pharma First Quarter 2024 Earnings: Beats Expectations

BBIO

Simply Wall St.

7 months ago

BridgeBio Pharma First Quarter 2024 Earnings: Beats Expectations

BridgeBio Oncology Therapeutics launches with $200m funding

BBIO

Pharmaceutical Technology

7 months ago

BridgeBio Oncology Therapeutics launches with $200m funding

BBIO

MT Newswires

7 months ago

BridgeBio Pharma Shares Decline After Q1 Financial Results

BBIO

Associated Press Finance

7 months ago

BridgeBio Pharma: Q1 Earnings Snapshot

BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update

BBIO

GlobeNewswire

7 months ago

BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update

BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline

BBIO

GlobeNewswire

7 months ago

BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline

BridgeBio spinout launches with $200M for KRAS cancer drugs

BBIO

BioPharma Dive

7 months ago

BridgeBio spinout launches with $200M for KRAS cancer drugs

Pfizer’s strong Vyndaqel sales draw attention to rare disease drug’s patent life

BBIO

BioPharma Dive

7 months ago

Pfizer’s strong Vyndaqel sales draw attention to rare disease drug’s patent life

BBIO

Zacks

7 months ago

Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should Know

BBIO

GlobeNewswire

7 months ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

BBIO

GlobeNewswire

7 months ago

BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

BBIO

TipRanks

8 months ago

TipRanks’ ‘Perfect 10’ List: These 3 Top-Scoring Stocks Are Sending a Bullish Signal

BBIO

GlobeNewswire

8 months ago

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BridgeBio Pharma Announces Pricing of Public Offering of Common Stock

BBIO

GlobeNewswire

9 months ago

BridgeBio Pharma Announces Pricing of Public Offering of Common Stock

Bayer (BAYRY) Acquires BridgeBio's Cardiovascular Drug

BBIO

Zacks

9 months ago

Bayer (BAYRY) Acquires BridgeBio's Cardiovascular Drug

BridgeBio Pharma Announces Proposed Public Offering of Common Stock

BBIO

GlobeNewswire

9 months ago

BridgeBio Pharma Announces Proposed Public Offering of Common Stock

BridgeBio Dives After Inking A $310 Million Deal With Bayer For Its Lead Drug

BBIO

Investor's Business Daily

9 months ago

BridgeBio Dives After Inking A $310 Million Deal With Bayer For Its Lead Drug

Bayer pays $310M to buy into BridgeBio heart drug

BBIO

BioPharma Dive

9 months ago

Bayer pays $310M to buy into BridgeBio heart drug

BBIO

Reuters

9 months ago

BridgeBio Pharma, Bayer agree on licensing deal for heart disease drug in Europe

BridgeBio, A Top 3% Biotech, Just Snagged A $310 Million Deal; Will Shares Break Out?

BBIO

Investor's Business Daily

9 months ago

BridgeBio, A Top 3% Biotech, Just Snagged A $310 Million Deal; Will Shares Break Out?

BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM

BBIO

GlobeNewswire

9 months ago

BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM

BridgeBio Pharma Full Year 2023 Earnings: Misses Expectations

BBIO

Simply Wall St.

9 months ago

BridgeBio Pharma Full Year 2023 Earnings: Misses Expectations

BBIO

Zacks

9 months ago

BridgeBio Pharma (BBIO) Reports Q4 Loss, Lags Revenue Estimates

BBIO

Associated Press Finance

9 months ago

BridgeBio Pharma: Q4 Earnings Snapshot

BBIO

GuruFocus.com

9 months ago

BridgeBio Pharma Inc (BBIO) Reports Q4 and Full Year 2023 Financials, Advances Key Clinical Trials

BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update

BBIO

GlobeNewswire

9 months ago

Latest BridgeBio Pharma Inc. (BBIO) News on November 21, 2024

Share on Social Networks: